Takeda to distribute Y-mAbs' cancer antibody treatment in Israel

By The Science Advisory Board staff writers

Y-mAbs and Takeda Israel, a subsidiary of Takeda Pharmaceutical, have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of naxitamab-gqgk (Danyelza) and omburtamab.

Danyelz was approved by the U.S. Food and Drug Administration (FDA) on November 25, for the treatment of with relapsed/refractory high-risk neuroblastoma. Y-mAbs plans to resubmit an amended biologics license application for omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or early in 2021. Omburtamab targets tumors that express B7-H3.

Under the agreement, Takeda will be responsible for the sales, access, marketing, and regulatory activities to distribute Danyelza and omburtamab in the territory (State of Israel, West Bank, and Gaza Strip). All other geographies worldwide remain with Y-mAbs.

Financial details of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?